[EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2014079150A1
公开(公告)日:2014-05-30
Provided are compounds of formula (I), which can inhibit glutaminase. Pharmaceutical compositions comprising these compounds and uses as glutaminase inhibitors for treating cancers thereof are also provided.
[EN] COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF<br/>[FR] COMPOSÉS, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS DES COMPOSÉS EN TANT QU'INHIBITEURS DE GLUTAMINASE POUR LE TRAITEMENT DE CANCERS ASSOCIÉS
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2014079136A1
公开(公告)日:2014-05-30
Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.
Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
[EN] SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] COMPOSÉS SPIRO EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE 4 ET LEURS UTILISATIONS
申请人:PFIZER
公开号:WO2021250541A1
公开(公告)日:2021-12-16
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I):
[wherein —X—Y-Z- represents —O—CR
3
═N— (wherein R
3
represents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, R
1
represents —NR
10
R
11
(wherein R
10
and R
11
may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like) and the like, R
2
represents —NR
13
R
14
(wherein R
13
and R
14
may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)] or a pharmaceutically acceptable salt thereof.